MedTrace Logo

Study of Nolasiban to Increase Pregnancy Rates in Women Undergoing IVF

NCT03758885 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 820

Last updated 2021-09-09

No results posted yet for this study

Summary

The primary objective of this study is to confirm the efficacy of a single oral 900 mg dose of nolasiban versus placebo to increase the ongoing clinical pregnancy rate at 10 weeks post-embryo transfer (ET) day.

Conditions

Interventions

DRUG

Nolasiban

Nolasiban single oral administration

DRUG

Placebo

Placebo single oral administration

Sponsors & Collaborators

  • ObsEva SA

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
37 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-10
Primary Completion
2019-11-21
Completion
2020-11-11

Countries

  • Belgium
  • Canada
  • Czechia
  • Denmark
  • Estonia
  • Germany
  • Hungary
  • Poland
  • Russia
  • Spain

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03758885 on ClinicalTrials.gov